These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8549757)

  • 1. Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-beta receptor type III extracellular domain.
    Pepin MC; Beauchemin M; Collins C; Plamondon J; O'Connor-McCourt MD
    FEBS Lett; 1995 Dec; 377(3):368-72. PubMed ID: 8549757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scanning-deletion analysis of the extracellular domain of the TGF-beta receptor type II.
    Pepin MC; Beauchemin M; Plamondon J; O'Connor-McCourt MD
    Biochem Biophys Res Commun; 1996 Mar; 220(2):289-93. PubMed ID: 8645298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex.
    Hart PJ; Deep S; Taylor AB; Shu Z; Hinck CS; Hinck AP
    Nat Struct Biol; 2002 Mar; 9(3):203-8. PubMed ID: 11850637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a recombinant bacterial expression system for the active form of a human transforming growth factor beta type II receptor ligand binding domain.
    Boesen CC; Motyka SA; Patamawenu A; Sun PD
    Protein Expr Purif; 2000 Oct; 20(1):98-104. PubMed ID: 11035957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling.
    Shimanuki T; Hara T; Furuya T; Imamura T; Miyazono K
    Oncogene; 2007 May; 26(23):3311-20. PubMed ID: 17146441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor-binding sequence in human alpha2-macroglobulin targets the receptor-binding site in transforming growth factor-beta.
    Arandjelovic S; Freed TA; Gonias SL
    Biochemistry; 2003 May; 42(20):6121-7. PubMed ID: 12755614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
    Thompson TB; Lerch TF; Cook RW; Woodruff TK; Jardetzky TS
    Dev Cell; 2005 Oct; 9(4):535-43. PubMed ID: 16198295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
    Deng X; Bellis S; Yan Z; Friedman E
    Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway.
    Santander C; Brandan E
    Cell Signal; 2006 Sep; 18(9):1482-91. PubMed ID: 16413747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of recognition site between transforming growth factor-beta1 (TGF-beta1) and TGF beta receptor type II: possible implications in breast cancer.
    Ivanović V; Demajo M; Todorović-Raković N; Nikolić-Vukosavljević D; Nesković-Konstantinović Z; Krtolica K; Veljković V; Prljić J; Dimitrijević B
    Med Hypotheses; 2004; 62(5):727-32. PubMed ID: 15082097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An emerging complexity of receptors for transforming growth factor-beta.
    Derynck R; Chen RH; Ebner R; Filvaroff EH; Lawler S
    Princess Takamatsu Symp; 1994; 24():264-75. PubMed ID: 8983081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport.
    Belville C; Maréchal JD; Pennetier S; Carmillo P; Masgrau L; Messika-Zeitoun L; Galey J; Machado G; Treton D; Gonzalès J; Picard JY; Josso N; Cate RL; di Clemente N
    Hum Mol Genet; 2009 Aug; 18(16):3002-13. PubMed ID: 19457927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino acid requirements for formation of the TGF-beta-latent TGF-beta binding protein complexes.
    Chen Y; Ali T; Todorovic V; O'leary JM; Kristina Downing A; Rifkin DB
    J Mol Biol; 2005 Jan; 345(1):175-86. PubMed ID: 15567420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-induced dimerization of the extracellular domain of the TGF-beta receptor type II.
    Letourneur O; Goetschy JF; Horisberger M; Grütter MG
    Biochem Biophys Res Commun; 1996 Jul; 224(3):709-16. PubMed ID: 8713111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
    Kuang C; Chen Y
    Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assembly of TbetaRI:TbetaRII:TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent.
    Zúñiga JE; Groppe JC; Cui Y; Hinck CS; Contreras-Shannon V; Pakhomova ON; Yang J; Tang Y; Mendoza V; López-Casillas F; Sun L; Hinck AP
    J Mol Biol; 2005 Dec; 354(5):1052-68. PubMed ID: 16289576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
    Lamken P; Gavutis M; Peters I; Van der Heyden J; Uzé G; Piehler J
    J Mol Biol; 2005 Jul; 350(3):476-88. PubMed ID: 15946680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagenesis of N-glycosylation sites in the human vasoactive intestinal peptide 1 receptor. Evidence that asparagine 58 or 69 is crucial for correct delivery of the receptor to plasma membrane.
    Couvineau A; Fabre C; Gaudin P; Maoret JJ; Laburthe M
    Biochemistry; 1996 Feb; 35(6):1745-52. PubMed ID: 8639654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors.
    Heegaard AM; Xie Z; Young MF; Nielsen KL
    J Cell Biochem; 2004 Oct; 93(3):463-75. PubMed ID: 15372625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.
    Mendoza V; Vilchis-Landeros MM; Mendoza-Hernández G; Huang T; Villarreal MM; Hinck AP; López-Casillas F; Montiel JL
    Biochemistry; 2009 Dec; 48(49):11755-65. PubMed ID: 19842711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.